+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Female Infertility Diagnosis And Treatment Market 2019-2025

  • ID: 4871641
  • Report
  • October 2019
  • Region: Global
  • Orion Market Research Private Limited

FEATURED COMPANIES

  • Bayer AG
  • Cook Medical, Inc.
  • Eli Lilly & Co.
  • Esco Group
  • Fairhaven Health, LLC
  • Ferring B.V.
Global Female Infertility Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Ovulation Testing, Ovarian Reserve Testing, Hormonal Level Testing, Hysterosalpingography (HSG), Hysteroscopy, Imaging Testing, Genetic Testing, and Others), by Treatment (Drugs, Surgery, Intrauterine Insemination (IUI), and ART), and by End-User (Hospitals and Clinics, Homecare, and Pathology and Diagnostic Centers) and Forecast 2019-2025.

The global female infertility diagnosis and treatment market is estimated to grow at a CAGR of 4% during the forecast period. Changing lifestyle and increasing the IVF market are the major factors propelling the growth of the global market. Furthermore, the rising trend of surrogacy, growing infertility rate among females, new technologies to avoid multiple embryo implants are also estimated to be the major factors that are contributing significantly towards the growth of the market. However, the high cost of infertility treatment, a low accuracy rate of the treatment, and social stigma related to the infertility treatment are the major constraints that are hindering the growth of the global market.

The global female infertility diagnosis and treatment market is segmented on the basis of diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into the ovulation testing, ovarian reserve testing, hormonal level testing, hysterosalpingography (HSG), hysteroscopy, imaging testing, genetic testing, and others. Based on the diagnosis, the market is fragmented into drugs, surgery, IUI, and ART. Among the type of treatments, the ART segment is projected to witness considerable growth in the market due to the continuous advancements in the ART. The market is further analyzed on the basis of end-users of the female infertility diagnosis and treatment, including hospitals and clinics, homecare, and pathology and diagnostic centers.

The global female infertility diagnosis and treatment market is further segmented on the basis of geography, including North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a significant share in the global market, owing to the rising prevalence of hormonal disorders caused by changing lifestyle, excessive alcohol consumption, lack of exercise, and stress. As per the study of the University of Maryland Medical Center (UMMC), in the US, around 10% of women aged between 15 and 44 are having difficulties in getting pregnant or carrying the pregnancy to full term. Asia-Pacific is considered an emerging market for female infertility diagnosis and treatment, owing to the presence of developing economies, growing awareness about methods such as IUI and IVF, and increasing per capita health care spending in the region.

The major market player of the female infertility diagnosis and treatment market includes Bayer AG, Pfizer Inc., Church & Dwight Co., Inc., Vitrolife, Genea Ltd., Ferring B.V., and Millendo Therapeutics Inc. These players are actively adopting growth strategies such as mergers and acquisitions, partnerships, collaboration and agreements to enhance their geographical reach. Innovative product development and new product launching are the core strength of key market players in the female infertility diagnosis and treatment market. For instance, in March 2018, Vitrolife AB had received approval for the sale of its time-lapse incubator EmbryoScope in the US. Through this approval, the company expanded its product portfolio and market presence in the US infertility treatment market.

Research Methodology

The market study of the global female infertility diagnosis and treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for infertility market players, research institutes, laboratories, clinics, medical professionals, government agencies, and related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:
1. Global Female Infertility Diagnosis and Treatment Market Research and Analysis by Diagnosis
2. Global Female Infertility Diagnosis and Treatment Market Research and Analysis by Treatment
3. Global Female Infertility Diagnosis and Treatment Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the global female infertility diagnosis and treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global female infertility diagnosis and treatment market.
  • Insights about market determinants which are stimulating the global female infertility diagnosis and treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Cook Medical, Inc.
  • Eli Lilly & Co.
  • Esco Group
  • Fairhaven Health, LLC
  • Ferring B.V.

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Bayer AG
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Pfizer Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. FIRST RESPONSE, a division of Church & Dwight Co., Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Vitrolife
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Genea Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Female Infertility Diagnosis and Treatment Market by Diagnosis
5.1.1. Ovulation Testing
5.1.2. Hysterosalpingography (HSG)
5.1.3. Hysteroscopy
5.1.4. Imaging Testing
5.1.5. Ovarian Reserve Testing
5.1.6. Hormonal Level Testing
5.1.7. Genetic Testing
5.1.8. Others (Laparoscopy)
5.2. Global Female Infertility Diagnosis and Treatment Market by Treatment
5.2.1. Drugs
5.2.2. Surgery
5.2.3. Intrauterine Insemination (IUI)
5.2.4. Assisted Reproductive Technology (ART)
5.3. Global Female Infertility Diagnosis and Treatment Market by End-User
5.3.1. Hospitals and Clinics
5.3.2. Homecare
5.3.3. Pathology and Diagnostic Centers
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Bayer AG
7.2. Clearblue, a company of SPD Swiss Precision Diagnostics GmbH
7.3. Cook Medical, Inc.
7.4. Eli Lilly & Co.
7.5. Esco Group
7.6. Fairhaven Health, LLC
7.7. Ferring B.V.
7.8. FIRST RESPONSE, a division of Church & Dwight Co., Inc.
7.9. FUJIFILM Irvine Scientific, Inc.
7.10. Genea Ltd.
7.11. GlaxoSmithKline Plc.
7.12. Merck KGaA
7.13. Millendo Therapeutics Inc.
7.14. Pfizer Inc.
7.15. Vitrolife
7.16. Princeton BioMeditech Corp.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bayer AG
  • Clearblue, a company of SPD Swiss Precision Diagnostics GmbH
  • Cook Medical, Inc.
  • Eli Lilly & Co.
  • Esco Group
  • Fairhaven Health, LLC
  • Ferring B.V.
  • FIRST RESPONSE, a division of Church & Dwight Co., Inc.
  • FUJIFILM Irvine Scientific, Inc.
  • Genea Ltd.
  • GlaxoSmithKline Plc.
  • Merck KGaA
  • Millendo Therapeutics Inc.
  • Pfizer Inc.
  • Vitrolife
  • Princeton BioMeditech Corp.
Note: Product cover images may vary from those shown